Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin and Erlotinib in Advanced Solid Tumors and NSCLC
NCT00452413Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2007
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzastaurin in non-small cell lung cancer (NSCLC) and solid tumor, sponsored by Eli Lilly and Company. Primary endpoints: Recommended Phase 2 Dose and Progression-Free Survival up to 20 months. Started May 2007; status: completed.
02
Drugs
enzastaurin
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT00452413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00452413.